User login
Key clinical point: The modified triplet (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan [mFOLFOXIRI]) + panitumumab vs. the doublet (fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) + panitumumab does not show improved activity as initial therapy for RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC).
Major finding: Patients receiving mFOLFOXIRI + panitumumab vs. FOLFOX + panitumumab showed no significant difference in the objective response rate (73% vs. 76%; odds ratio 0.87; P = .526) and median progression-free survival (12.7 vs. 12.3 months; hazard ratio 0.88; P = .277).
Study details: Findings are from the phase 3 TRIPLETE study that included 435 adult patients with RAS and BRAF wt mCRC who were randomly assigned to receive mFOLFOXIRI + panitumumab (n = 218) or FOLFOX + panitumumab (n = 217).
Disclosures: The study was supported by the GONO Foundation and Amgen. Some authors declared serving as consultants/advisors or members of the speaker's bureau for or receiving honoraria, research funding, or travel and accommodation fees from various sources, including Amgen.
Source: Rossini D et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer: The phase III TRIPLETE Study by GONO. J Clin Oncol. 2022 (Jun 6). Doi: 10.1200/JCO.22.00839
Key clinical point: The modified triplet (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan [mFOLFOXIRI]) + panitumumab vs. the doublet (fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) + panitumumab does not show improved activity as initial therapy for RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC).
Major finding: Patients receiving mFOLFOXIRI + panitumumab vs. FOLFOX + panitumumab showed no significant difference in the objective response rate (73% vs. 76%; odds ratio 0.87; P = .526) and median progression-free survival (12.7 vs. 12.3 months; hazard ratio 0.88; P = .277).
Study details: Findings are from the phase 3 TRIPLETE study that included 435 adult patients with RAS and BRAF wt mCRC who were randomly assigned to receive mFOLFOXIRI + panitumumab (n = 218) or FOLFOX + panitumumab (n = 217).
Disclosures: The study was supported by the GONO Foundation and Amgen. Some authors declared serving as consultants/advisors or members of the speaker's bureau for or receiving honoraria, research funding, or travel and accommodation fees from various sources, including Amgen.
Source: Rossini D et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer: The phase III TRIPLETE Study by GONO. J Clin Oncol. 2022 (Jun 6). Doi: 10.1200/JCO.22.00839
Key clinical point: The modified triplet (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan [mFOLFOXIRI]) + panitumumab vs. the doublet (fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) + panitumumab does not show improved activity as initial therapy for RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC).
Major finding: Patients receiving mFOLFOXIRI + panitumumab vs. FOLFOX + panitumumab showed no significant difference in the objective response rate (73% vs. 76%; odds ratio 0.87; P = .526) and median progression-free survival (12.7 vs. 12.3 months; hazard ratio 0.88; P = .277).
Study details: Findings are from the phase 3 TRIPLETE study that included 435 adult patients with RAS and BRAF wt mCRC who were randomly assigned to receive mFOLFOXIRI + panitumumab (n = 218) or FOLFOX + panitumumab (n = 217).
Disclosures: The study was supported by the GONO Foundation and Amgen. Some authors declared serving as consultants/advisors or members of the speaker's bureau for or receiving honoraria, research funding, or travel and accommodation fees from various sources, including Amgen.
Source: Rossini D et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer: The phase III TRIPLETE Study by GONO. J Clin Oncol. 2022 (Jun 6). Doi: 10.1200/JCO.22.00839